Presentation from OIS@ASCRS 2016 Nick Tarantino, OD, Chief Global Clinical & Regulatory Affairs Officer Video Presentation: https://www.youtube.com/watch?v=Nc4T9u62rBQ&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=34

1. Nicholas Tarantino, OD
Chief Clinical & Regulatory Officer
OIS
May 5, 2015

2. KAMRA® Inlay (Ages 45-60)
FDA approved; commercially available in 50 countries
6 μm
Thick
8,400 micro-perforations (5-
11 μm) allow nutrient flow
Inlay matches
corneal curvature




1.6mm
Central
Aperture
Improves near vision with minimal impact to distance
vision
− Achieves long-lasting results even as presbyopia progresses
Implanted into corneal pocket created with femtosecond
laser
− Implanted monocularly into non-dominant eye
Removable via low-risk procedure with recovery of pre-
inlay vision
Made from Polyvinylidene Fluoride (PVDF)
3.8 mm
Diameter
KAMRA Inlay: Effective, Reliable Presbyopia Solution
 Thickness less than the size of a red blood cell
2

3. KAMRA® Inlay Commercial Success in the US
• The KAMRA inlay is the first product to be designed and approved for
treatment of presbyopia in over a decade
• Controlled product launch nationally
• Exceeding every internal metric within the first 12 months
Details Key Dates & Metrics
KAMRA® inlay approval Approved April 17, 2015
Commercial KAMRA inlay launch June 2015
Total number of inlays implanted 2000+
Percent of surgeons who have reordered 82.5%
Average reorder time 1 month
Monthly implant growth since launch 200%
3

4. Small Aperture Comes to the United States
KAMRA® Inlay Approved April 17, 2015
Mean Visual Acuity in KAMRA® Inlay Eye
Number of Patients Uncorrected DVA Uncorrected NVA
Pre-op 504 20/25 J6
1 Month 344 20/28 J2
3 Months 196 20/27 J2
6 Months 52 20/25 J2
Mean Bilateral Visual Acuity
Number of Patients Uncorrected DVA Uncorrected NVA
Pre-op 526 20/22 J6
1 Month 336 20/20 J2
3 Months 200 20/20 J2
6 Months 52 20/20 J2
4

5. The KAMRA® Inlay Pull Through Effect
Accelerating Growth in Refractive Practices
Average % Growth Since Adding the KAMRA Inlay
23%
67%
27%
10%
0%
20%
40%
60%
80%
100%
LASIK Mul focal IOL Toric IOL Accommoda ve
IOL
5

6. IC-8™ IOL Specifications
Approved in Europe, Australia and New Zealand
• Material - Benz R&D HF1.2 Hydrophobic Acrylic
– Optical purity >99.98%
– Water content <4%
– Refractive index: 1.483
– ABBE No. 49
• Optical Design
– Single piece 360o square edge
– 6.00 mm optic diameter
– 12.50 mm overall diameter
– 5o Haptic angulation
– Spherical posterior surface
– Aspheric anterior surface
– A-constant = 120.4
– ACD 6.60
• Single-Use Injector System – (current)
– 3.5 mm incision for capsular bag insertion, non-folding
– 2.8 mm incision under development
IOL Material
Single-piece hydrophobic acrylic
Mask
PVDF & nano-particles of carbon
1.36mm aperture
3.23mm total diameter
3200 microperforations
5 microns thick
6

7. Binocular Defocus Curves:
Distance-corrected and Target-corrected IC-8™ IOL with Monofocal IOL
-0.3
-0.2
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
-4-3-2-1012
VisualAcuity(logMAR)
Defocus (D)
Binocular Defocus Curve
(IC-8 with monofocal IOL, Distance-Corrected vs Target-Corrected)
Acual Distance-
correced OU
(n=95)
Actual Target-
corrected IC-
8/Distance-
corrected mono
(n=6)
• Target-correcting the IC-8 IOL eye to -0.75 D while keeping the monofocal
IOL at plano adds near vision without sacrificing distance vision
7

8. IC-8™ IOL Visual Acuity Results
Uncorrected and Target-Corrected Mean Visual Acuities
Number of
Patients
Uncorrected DVA Uncorrected IVA Uncorrected NVA
1 Month 102 20/20 20/20 20/32
3 Months 93 20/20 20/20 20/32
6 Months 63 20/16 20/20 20/25
Number of
Patients
Target-Corrected
DVA*
Target-Corrected
IVA*
Target-Corrected
NVA*
1 Month 102 20/20 20/20 20/25
3 Months 93 20/20 20/20 20/25
6 Months 63 20/16 20/20 20/25
• Visual Acuities at 1, 3, and 6 months
* Target correction is -0.75 for IC-8 eye and plano for monofocal eye
8

9. Competitive Comparison of IOL Image Quality
IC-8™ IOL has the broadest range of high quality continuous functional vision
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
AT LISA Tri
IC-8, SA
TECNIS Mono
ReSTOR 3.00
TECNIS 2.75
Symfony
Through Focus Image Quality Bench Test Data, 50 lp/mm, ISO Model Eye, White Light
(Halogen 440 - 755 nm), in Aqueous
MTFImageQuality,50lp/mm
Relative Defocus (Diopter)
-1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0
Unusable
Vision
9

10. 0.0D +0.5D +1.0D +1.5D +2.0D +3.0D
AcuFocus IC-8™ IOL (Target-corrected to -0.75D)
Symfony IOL
AcriLisa Trifocal IOL
(Far Focus) (Near Focus)
Defocus Image Data – White Light, ISO Model Eye, In Aqueous
Monocular Through Focus Imaging
IC-8™ IOL vs. Symfony IOL & AcriLisa Trifocal IOL
10

11. Tolerance to Uncorrected Astigmatism
(IC-8™ Eyes vs. Monofocal Eyes)
0
0.05
0.1
0.15
0.2
0.25
0.3
-3-2.5-2-1.5-1-0.50
ChangeinVisualAcuity(logMAR)
Cylinder Defocus
Cylinder Defocus Curves
IC-8 IOL vs Monofocal IOL
IC-8
Monofocal
N=10
One line of loss
• Change in distance visual acuity compared to the visual acuity corrected at
manifest refraction at each cylinder defocus step was plotted against cylinder
defocus steps(0.50 D steps)
• The IC-8 IOL is capable of addressing 82% of cataract patients (< 1.50 D) presenting
with astigmatism without the need for additional incisional procedures or axis
alignment
11

12. Therapeutic Uses for the IC-8™ IOL
Positive Results for Therapeutic Applications Extends IOL Value
Images courtesy of Burkhard Dick, MD
• Therapeutic uses for small aperture IOL
– Highly aberrated corneas
• Post RK
• Post LASIK
– Iris abnormalities
• CASE EXAMPLE: Iris Trauma
– Pre-op
• Visual acuity = 0.2 (+18 D)
• Complains of significant glare/light
sensations/photophobia
– 3 days post-IC-8™ IOL insertion
• UCDVA: 1.0p, UCNVA: 0.8
• Patient: very happy, no glare, no
light blindness
Case example and images courtesy of Prof Burkhard Dick
12

13. What Does All This Mean
“We are facing a real revolution with the IC-8 IOL. This
technology has overcome the older one . . . multifocals
and bifocals will disappear soon from our surgical field.”
Matteo Piovella, M.D.
“The IC-8 is the lens for everybody.”
Prof. Burkhard Dick, M.D.
“IC-8 in my opinion is the best IOL for patients who were
treated for corneal refractive surgery “
Simonetta Morselli, M.D.
13

14. Small Aperture Solution
Presbyopia and cataract solutions for unmet physician and patient needs
KAMRA® Inlay IC-8™ IOL
• No. 1 corneal inlay with +5-year
clinical track record and 20K implanted
worldwide
• Only US approved corneal-based
premium procedure labeled both for
extended depth of focus (EDOF) and
presbyopia correction
• Available in 50 countries
• Long-lasting, complete, natural range
of vision; minimally invasive; reversible
• Treats wide patient range: early
emmetropic presbyopes
• New EDOF IOL with favorable clinical
experience
• CE Marked with EDOF labeling,
approved in Australia
• Monocular implantation with results
similar to KAMRA inlay
• Overcomes other PC-IOL limitations
(incomplete range of vision,
unreliability, glare/halo,
neuroadaptation)
• Ideal for cataract-age presbyopes
14
Extended Depth-of-Focus with Small Aperture Optics

15. THANK YOU
15